Xiaotian Zhu
Shenyang Ligong University(CN)Jimei University(CN)Chinese Academy of Sciences(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Research Studies
Most-Cited Works
- → Structural Analysis of Substrate Binding by the Molecular Chaperone DnaK(1996)1,254 cited
- → AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance(2009)1,234 cited
- → Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase(2016)396 cited
- → Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant(2010)358 cited
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited